Literature DB >> 8940212

Effect of ethambutol on emergence of clarithromycin-resistant Mycobacterium avium complex in the beige mouse model.

L E Bermudez1, K A Nash, M Petrofsky, L S Young, C B Inderlied.   

Abstract

An animal model was developed for studying macrolide-resistant Mycobacterium avium complex (MAC) and to measure the effect of ethambutol on resistance. MAC-infected beige mice were given clarithromycin daily; the frequency of clarithromycin-resistant MAC after 8 and 12 weeks was 10(-3) and 10(-2), respectively. Combined ethambutol plus clarithromycin did not increase anti-MAC activity, but clarithromycin-resistant MAC was less frequent (P < .05). The frequency of clarithromycin-resistant MAC in mice receiving the combination was significantly higher than that in untreated mice. These results are consistent with two human trials, which showed that adding ethambutol reduced the frequency of clarithromycin-resistant MAC. Results of the present study suggest that with an initially high level of MAC infection, the addition of ethambutol may only delay resistance. This mouse test system will be useful for investigating the influence of the level of MAC infection and the effect of other drugs on the frequency of resistant MAC.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8940212     DOI: 10.1093/infdis/174.6.1218

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  6 in total

1.  Effect of drug concentration on emergence of macrolide resistance in Mycobacterium avium.

Authors:  K A Nash
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

2.  Clarithromycin-resistant mycobacterium avium is still susceptible to treatment with clarithromycin and is virulent in mice.

Authors:  L E Bermudez; K Nash; M Petrofsky; L S Young; C B Inderlied
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

3.  Emergence of Mycobacterium avium populations resistant to macrolides during experimental chemotherapy.

Authors:  L E Bermudez; M Petrofsky; P Kolonoski; L S Young
Journal:  Antimicrob Agents Chemother       Date:  1998-01       Impact factor: 5.191

4.  Antimycobacterial agents differ with respect to their bacteriostatic versus bactericidal activities in relation to time of exposure, mycobacterial growth phase, and their use in combination.

Authors:  Irma A J M Bakker-Woudenberg; Wim van Vianen; Dick van Soolingen; Henri A Verbrugh; Michiel A van Agtmael
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

5.  Relationship between Resistance to Ethambutol and Rifampin and Clinical Outcomes in Mycobacterium avium Complex Pulmonary Disease.

Authors:  Seong Mi Moon; Su-Young Kim; Dae Hun Kim; Hee Jae Huh; Nam Yong Lee; Byung Woo Jhun
Journal:  Antimicrob Agents Chemother       Date:  2022-03-10       Impact factor: 5.938

Review 6.  Mycobacterium abscessus: It's Complex.

Authors:  Hazem F M Abdelaal; Edward D Chan; Lisa Young; Susan L Baldwin; Rhea N Coler
Journal:  Microorganisms       Date:  2022-07-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.